Positive Results from Phase 3 Trial of Combo Therapy for Multiple Myeloma Presented at ASCO 2016
Researchers from Janssen Research & Development presented promising interim results from the Phase 3 MMY3004 (CASTOR) clinical trial, assessing the immunotherapy drug daratumumab (Darzalex) against standard of care in previously treated multiple myeloma patients, at the recent American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago. Specifically, the ongoing trial (NCT02136134) showed…